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Background
This two-stage, multi-institutional, randomized phase 2 trial assessed the toxicity and
response rate associated with two treatment schedules of the histone deacetylase
inhibitor, vorinostat (suberoylanilide hydroxamic acid; SAHA) in patients with relapsed
acute myeloid leukemia and in selected untreated patients with high-risk acute myeloid
leukemia. 
Design and Methods
Patients with relapsed or untreated acute myeloid leukemia who were not candidates for
chemotherapy entered one of the two treatment arms. In both arms a total dose of 8400
mg of vorinostat was delivered in each 21-day cycle of treatment: in arm A the dose regi-
men was 400 mg daily whereas in arm B the dose regimen was 200 mg three times daily
for 14 days followed by 1 week rest. 
Results
Data from all 37 patients were used for the analyses. In arm A (n=15), the confirmed com-
plete remission rate was 0% (95% CI, 0% to 23%); this arm was closed at the planned
interim analysis. In arm B (n=22), the confirmed complete remission rate was 4.5% (1
response; 95% CI, 0.4% to 24%), with a duration of response exceeding 398 days. The
median time to treatment failure in arm A was 42 days (95% CI, 26 to 57); although a min-
imum of four cycles of treatment were planned, 11 patients (79%) received no more than
two cycles. The median time to treatment failure in arm B was 46 days (95% CI, 20 to 71);
13 patients (59%) received no more than two cycles of treatment. 
Conclusions
Vorinostat monotherapy demonstrated minimal activity in this group of patients with
acute myeloid leukemia. Therapy was discontinued in many patients before the planned
four cycles had been administered, either because of failure of vorinostat to control the
leukocyte count or patients’ and physicians’ preference. Future studies of vorinostat in
acute myeloid leukemia should focus on combinations with other drugs with which it
might interact pharmacodynamically. ClinicalTrials.gov Identifier: NCT00305773.
Key words: acute myeloid leukemia, acute myeloid leukemia, HDAC, histone deacetylase
inhibitor, phase 2, SAHA, suberoylanilide hydroxamic acid, vorinostat.
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Introduction
Current chemotherapy regimens lead to long-term dis-
ease-free survival in approximately 25-30% of adults
with acute myeloid leukemia (AML) younger than 60
years;1-4 in older patients, fewer than 10% of patients sur-
vive 2 years. As many as 30% of newly-diagnosed
patients with AML prove refractory to induction therapy,
especially those whose disease has evolved from a
myelodysplastic syndrome or another antecedent hema-
tologic disorder or is related to exposure to environmen-
tal/occupational toxins.5 Current approaches to these
high-risk subsets of AML yield complete remissions in
40% of patients or less; the complete remissions are usu-
ally brief (<12 months) and few cures are achieved. Thus,
the development of novel treatment approaches remains
critical for patients with relapsed and poor-risk untreated
AML.6
Histone deacetylase (HDAC) inhibitors have under-
gone early stage investigation in AML over the past sev-
eral years. HDAC and histone acetyltransferases regulate
the acetylation of histone proteins, setting the transcrip-
tional activity of chromatin at specific gene loci. These
proteins also regulate the acetylation of non-histone pro-
teins, including transcription factors involved in cell cycle
progression and apoptosis.7-9 HDAC inhibition may help
to establish more normal transcription patterns through
chromatin remodeling since many cancers, including
AML, have aberrant acetylation patterns leading to tran-
scriptional silencing of tumor suppressor genes.10-17 In
addition to their impact on gene transcription, HDAC
inhibitors have a variety of potentially important effects,
which could be beneficial in the treatment of AML.
These include the induction of reactive oxygen species,
induction of oxidative damage to DNA, inactivation of
HSP90 chaperone function, and an effect on NFκB signal-
ing.18
Vorinostat (suberoylanilide hydroxamic acid, SAHA), a
hydroxamic acid inhibitor of class I and class II HDAC,16
was approved in the United States for the treatment of
recurrent cutaneous T-cell lymphoma. Vorinostat induces
cell cycle arrest and apoptosis in cancer cell lines, has
demonstrated activity against leukemia and other hema-
tologic malignancies in vitro19-30 and also improved survival
and/or produced antitumor effects in rodent models of
leukemia.31 In a phase I study of vorinostat in patients
with myeloid leukemias four of six patients receiving
vorinostat orally at a dose of 200 mg t.i.d. 14 days on/7
days off developed clinical responses: complete response
(n=1); complete response with incomplete platelet recov-
ery (n=1), clearance of marrow blasts (n=2).32
The current phase 2 trial was designed to independent-
ly assess the toxicity and response rate associated with
this schedule of vorinostat administration in patients
with AML. In addition, this trial assessed the toxicity and
response rate associated with a lower daily dose admin-
istered continuously to deliver the same total dose over
21 days, to explore whether continuous exposure to




National Cancer Institute protocol 6882 was an open-
label randomized phase 2 study of two schedules of
vorinostat administration in patients with relapsed AML
and selected untreated patients with high-risk AML.
Patients were planned to receive a minimum of four 21
day 21-day cycles of vorinostat before response was eval-
uated. Concomitant hydroxyurea was allowed during
the first two cycles; however, in patients whose white
blood cell (WBC) count could not be maintained under
30×109/L without hydroxyurea following two cycles of
vorinostat, treatment was considered to have failed.
Patients could continue to receive vorinostat for 17 cycles
in the absence of disease progression. The protocol was
approved by the Institutional Review Boards of the
Institutions involved, and all patients provided written
informed consent in accordance with the Declaration of
Helsinki before enrollment following institutional guide-
lines.
Eligibility criteria and patients
Patients with relapsed AML, including those with core
binding factor leukemias in second relapse or in first
relapse following a remission of less than 12 months,
were eligible for enrollment. Patients with untreated
AML were eligible if one of the following conditions
were met: age 65 years or older; AML with antecedent
myelodysplastic syndrome (AML with trilineage dyspla-
sia); AML with poor-risk cytogenetics (del5q, monosomy
5, monosomy 7, or complex cytogenetics defined as ≥3
cytogenetic abnormalities). Untreated patients were
required to be ineligible for potentially curative therapy
or have declined such therapy. 
Patients in both groups were required to have normal
organ function defined as: total bilirubin within normal
institutional limits unless attributed to hemolysis or
Gilbert’s disease; aspartate and alanine transaminases less
than or equal to 2.5 times the institutional upper limit of
normal (ULN); and creatinine concentration less than or
equal to the institutional ULN or creatinine clearance 60
mL/min/1.73 m2 or more for patients with creatinine lev-
els above the institutional normal. In addition, all patients
were required to be at least 18 years old, have a life
expectancy of at least 3 months, and an Eastern
Cooperative Oncology Group performance status no
greater than 2 or a Karnofsky score of at least 60%. 
Patients were not allowed to have received other treat-
ment for AML, including hematopoietic growth factors,
within 3 weeks prior to study registration with the
exception of hydroxyurea, which was allowed to be
administered to patients with a WBC count greater than
30×109/L according to the treating institutions’ standard
clinical practice. Radiotherapy (within 4 weeks of regis-
tration), valproic acid (within 2 weeks), and concurrent
use of any other investigational agents were also not
allowed. Other exclusion criteria included: clinical evi-
dence of central nervous system (CNS) or pulmonary
leukostasis, disseminated intravascular coagulation, or
CNS leukemia; history of allergic reactions attributed to
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compounds of similar chemical or biological composition
to vorinostat, uncontrolled intercurrent illness; and
known positivity for human immunodeficiency virus.
Treatment plan
Vorinostat was supplied by Merck through the National
Cancer Institute Cancer Therapy Evaluation Program.
Patients were randomized to one of two treatment arms
of oral vorinostat. In arm A, vorinostat was delivered at
400 mg daily for the full cycle of 21 days; in arm B, vorino-
stat was administered at 200 mg t.i.d. on days 1-14 of
each 21-day cycle. In patients receiving concomitant
hydroxyurea, the hydroxyurea was withdrawn on day 15
of cycles 1 and 2 to assess WBC count under the influence
of vorinostat alone. Patients failing to achieve a WBC
count below 30×109/L after two cycles were removed
from the study and the treatment was considered to have
failed. Dose adjustments were allowed for both hemato-
logic and non-hematologic toxicities, with 300 mg daily
for arm A and 200 mg b.i.d. for arm B being the first lev-
els of dose reduction.
The patients’ responses were assessed using the
International Working Group Criteria for responses in
AML and included morphologic complete response (CR),
partial response (PR) and hematologic improvement
(HI).33 Responses were confirmed if they persisted for two
consecutive cycles at least 4 weeks apart. Peripheral blood
and bone marrow parameters measured after cycles 4 and
6 were used to determine response, and patients respond-
ing at cycle 6 continued the treatment with response
measured every three cycles.
Safety was assessed through adverse event reporting
and the monitoring of vital signs and laboratory parame-
ters. Hospital admissions and deaths were reviewed and
classified using information from the hospital records,
death certificates, and interviews with primary care
physicians and next-of-kin.
Statistical design
This randomized phase 2 trial with an interim analysis
was designed to independently assess the confirmed CR
rate in each arm. The same design was used in each arm,
and required a minimum of 13 and a maximum of 20
patients to test the null hypothesis that the confirmed CR
rate was at most 5% versus a specified alternative
hypothesis of at least 25%. An interim analysis was
planned once an arm had accrued 13 patients, and an arm
was only allowed to continue accrual if at least one
patient had an unconfirmed CR, PR or HI at the cycle-4
evaluation. Accrual was not suspended while awaiting
results of the interim analysis. The final decision criteria
required three successes in the first 20 enrolled patients to
claim effectiveness of the treatment arm. A success was
defined as a patient with a confirmed CR at any point
during treatment. The confirmed CR rate for each arm
was calculated as the number of successes divided by the
number of eligible patients. The overall power for each
arm was 90%, given a true confirmed CR rate of at least
25% and a type I error rate of 7.4%. No formal hypothe-
sis was established to test superiority between the indi-
vidual arms due to the limited sample sizes considered.
The number of successes was assumed to follow a
binomial distribution, and 95% confidence intervals (95%
CI) for the confirmed CR rate in each arm were calculat-
ed using the method of Duffy and Santner.34 The duration
of response was calculated as the time from date of doc-
umentation of first CR to the date of progression. Patients
without progression at last follow-up were considered
censored. The time to treatment failure (TTF) was defined
as the time from date of study registration until the date
of treatment discontinuation for any reason. Patients
receiving treatment at the time of analysis were consid-
ered censored. Overall survival was defined as the time
from date of registration until the date of death. Patients
alive at the last follow-up were considered censored. All




A total of 37 patients were enrolled into this trial
between January 25, 2006 and August 1, 2007. Fifteen
patients were enrolled in arm A, and 22 enrolled in arm B.
One patient in arm A was ineligible because of inappro-
priate use of hydroxyurea for a WBC count less than
30×109/L. However, because this use of hydroxyurea was
not likely to have affected the outcome of treatment, this
patient is included in all the analyses.
Five females were accrued in each arm; the median age
was 67 years in each arm (arm A range, 41 to 79; arm B
range, 28 to 81). Twelve patients (80%) in arm A and 16
patients (73%) in arm B had relapsed disease. The three
untreated patients (20%) in arm A were at least 65 years
old. Of the six patients (27%) in arm B with untreated dis-
ease, three were at least 65 years old, and three had a his-
tory of myelodysplastic syndrome. AML with trilineage
dysplasia was the diagnosis for 47% of the patients in
arm A and 41% in arm B. The randomization procedure
produced a general balance of the patients’ characteristics
between the arms, with the exception of a higher inci-
dence of infection within the previous 3 months among
patients in arm B (36% versus 13%). The characteristics
of the patients were similar between those with previous-
ly untreated and relapsed AML. The patients’ characteris-
tics are summarized in Tables 1 and 2.
Toxicity
Toxicities are listed by arm in Tables 3 and 4. In arm A,
grade 5 adverse events were reported in three patients
(20%). These events were pneumonia during the first
cycle of treatment, disease progression during the second
cycle, and death, not otherwise specified during the
fourth cycle. CNS hemorrhage, dizziness and fatigue
were the only grade 4 non-hematologic adverse events
reported. The patient reporting grade 4 dizziness subse-
quently died of pneumonia, and the patient experiencing
grade 4 CNS-hemorrhage also died. Grade 3 non-hemato-
logic adverse events were more common, with 26 events
reported for ten patients (67%). Seven of the ten patients
experienced at least one grade 3 non-hematologic adverse
event considered at least possibly related to treatment.
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reported for arm A were neutropenia and thrombocy-
topenia, both occurring in ten patients (67%), and all
patients had at least one thrombocytopenic event. Seven
patients (47%) experienced anemia, and six patients
(40%) experienced leukopenia. The most common
adverse events (>10%) in arm A, regardless of grade and
attribution, were thrombocytopenia (100%), neutropenia
(93%), fatigue (93%), anemia (47%), dyspnea (47%),
nausea (47%), leukopenia (40%), anorexia (27%), rash
(20%), diarrhea (20%), dizziness (13%), febrile neutrope-
nia (13%), and vomiting (13%).
In arm B, grade 5 events were experienced by two
patients (9%), both occurring during cycle 1. One patient
died from pneumonitis and one experienced sudden
death. Four patients (18%) experienced at least one grade
4 non-hematologic adverse event, although fatigue was
the only event considered possibly or probably related to
treatment. The other grade 4 non-hematologic adverse
events were pleuritic pain, CNS hemorrhage, hypoxia
and acidosis. The latter two events occurred in the same
| 1378 | haematologica | 2009; 94(10)
Table 1. Characteristics of the patients divided by treatment arm.
Characteristic Arm A Arm B 
(N=15) (N=22)
Age, median (range), years 67.0 (41.0-79.0) 67.0 (28.0-81.0)
Gender
Female 5 (33%) 5 (23%)
Male 10 (67%) 17 (77%)
Performance Score1
0 7 (47%) 8 (36%)
1 6 (40%) 10 (45%)
2 2 (13%) 3 (14%)
Associated diseases, yes 15 (100%) 22 (100%)
Disease status
Relapsed 12 (80%) 16 (73%)
Untreated 3 (20%) 6 (27%)
AML disease classification
All other relapsed AML 12 (80%) 16 (73%)
Untreated AML patients ≥65 years old 3 (20%) 3 (14%)
Untreated AML patients with MDS-AML 0 (0%) 3 (14%)
FAB classification2
AML with trilineage dysplasia 7 (47%) 9 (41%)
M0 1 (7%) 0 (0%)
M1 2 (13%) 5 (23%)
M2 2 (13%) 3 (14%)
M 40 (0%) 2 (9.1%)
M5a 1 (7%) 1 (4%)
M5b 1 (7%) 0 (0%)
M7 0 (0%) 1 (4%)
Previous stem cell transplant3 4 (27%) 3 (14%)
WBC (×109/L), median (range) 2.5 (0.9-48.5) 3.8 (0.7-74.3)
WBC counts of less than 5×109/L 10(71%) 14 (64%) 
WBC counts over 30×109/L 2(14%) 2 (9%)
Receiving hydroxyurea 4 (27 %) 4 (18)
Hemoglobin (g/dL), median (range) 9.5 (7.9-12.7) 9.7 (7.8-13.7)
Platelets (×109/L), median (range) 29.0 (5.0-176.0) 28.5 (11.0-141.0)
Absolute neutrophil count (×109/L), 0.6 (0.1-17.4) 0.5 (0.0-4.9)
median (range)
% Blasts, median (range) 18.0 (0.0-61.0) 2.0 (0.0-94.0)
% Bone marrow blasts, 
median (range) 48.5 (21.0-100.0) 37.0 (4.0-100.0)
Cytogenetics
Not done? 1 (7%) 1 (4%)
Normal 3 (20%) 6 (27%)
+8 0 (0%) 3 (14%)
Complex 4 (27%) 5 (23%)
Other 7 (47%) 7 (31.8%)
1One patient in arm B was assessed using the Karnofsky score,and had a score of
90. 2The FAB classification was not assessable for one patient in each arm. 3One
patient on arm B was not assessed for previous stem cell transplant.
Table 2. Characteristics of the patients divided according to whether




A 12 (43%) 3 (33%)
B 16 (57%) 6 (67%) 
Age, median (range), years 66.5 (28.0-79.0) 77.0 (66.0-81.0)
Gender
Female 8 (29%) 2 (22%)
Male 20 (71%) 7 (78%)
Performance Score1
0 14 (50%) 1 (12.5%)
1 11 (39%) 5 (62.5%)
2 3 (11%) 2 (25%)
Associated diseases, yes 28 (100%) 9 (100%) 
AML disease classification
All other relapsed AML 28 (100%) 0 (0%)
Untreated AML patients ≥65 years old 0 (0%) 6 (67%)
Untreated AML patients with MDS-AML 0 (0%) 3 (33%) 
FAB classification2
AML with trilineage dysplasia 13 (50%) 3 (33.3%)
M0 0 (0%) 1 (11.1%)
M1 6 (23%) 1 (11.1%)
M2 4 (15%) 1 (11.1%)
M4 1 (4%) 1 (11.1%)
M5a 0 (0%) 2 (22.2%)
M5b 1 (4%) 0 (0%)
M7 1 (4%) 0 (0%)
Previous stem cell transplant 7 (25%) 0 (0%)
WBC (×109/L), median (range) 2.4 (0.7-74.3) 7.6 (0.9-62.6)
WBC counts of less than 5×109/L 20 (71%) 4 (44%)
WBC counts over 30×109/L 3 (11%) 1 (11%)
Receiving hydroxyurea
Hemoglobin (g/dL), median (range) 9.5 (7.9-13.7) 9.1 (7.8-12.9)
Platelets (×109/L), median (range) 29.5 (10.0-176.0) 27.0 (5.0-90.0) 
Absolute neutrophil count (×109/L), 0.5 (0.0-17.4) 0.5 (0.1-4.9) 
median (range)
% Blasts, median (range) 9.5 (0.0-94.0) 22.0 (0.0-84.0) 
% Bone marrow blasts, 40.0 49.0
median (range) (4.0-100.0) (22.0-83.0) 
Cytogenetics
Not Done 1 (4%) 1 (11%)
Normal 7 (25%) 2 (22%)
+8 2 (7%) 1 (11%)
Complex 9 (32%) 0 (0%)
Other3 9 (32%) 5 (56%)
1One untreated patient was assessed using the Karnofsky score,and had a score of
90. 2The FAB classification was not assessable in one untreated patient. 3Untreated:
12p deletion; trisomy 13, trisomy 21; 13,deletion 7q; trisomy 11; -7 deletion arm1.
Relapsed: 8,21 (20); add(12p); inv(3), -7; del(20); 47,XYdel(1)p(13)[1]; add(1)
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patient who subsequently died of pneumonitis. Fifty-
three grade 3 non-hematologic adverse events were
reported for 17 patients (77%), with 36 of these events
(68%) being considered at least possibly related to treat-
ment. Grade 4 neutropenia occurred in 17 patients (77%),
and a maximum of grade 3 neutropenia occurred in three
other patients (14%). Grade 4 thrombocytopenia was
experienced by 13 patients (59%) with an additional six
patients (27%) having a maximum grade 3 event, and one
patient having a maximum grade 2 event. In addition,
anemia was experienced by seven patients (32%), and
leukopenia by four patients (18%). In arm B, the most
common adverse events (>10%), regardless of grade and
attribution, were fatigue (95%), neutropenia (91%),
thrombocytopenia (91%), nausea (73%), diarrhea (64%),
vomiting (45%), anorexia (41%), dyspnea (32%), anemia
(32%), febrile neutropenia (27%), leukopenia (18%),
pneumonia (14%), and abdominal pain (14%).
The incidence rates of grade 4 non-hematologic events
(20% in arm A versus 23% in arm B) and grade 3 non-
hematologic events (67% in arm A versus 68% in arm B)
were virtually the same. The incidences of the most com-
mon hematologic events were also similar, as revealed by
the rates of grade 4 neutropenia (67% versus 77%) and
grade 4 thrombocytopenia (67% versus 59%). However,
without regard to grade or attribution, there were differ-
ent rates of certain commonly noted adverse events (25%
incidence in at least one arm). While the 90% rates of
fatigue in each arm were similar, in arm B there were
higher rates of nausea (73% versus 47%), diarrhea (64%
versus 20%), anorexia (41% versus 27%), and vomiting
(45% versus 13%), whereas the rate of dyspnea was high-
er in arm A (47% versus 32%).
Dose modifications
In arm A, 31 cycles of treatment were administered to
15 patients. Three cycles were delayed in three separate
patients, and another patient had a dose reduction in the
second cycle. In arm B, 65 cycles of treatment were
administered to 22 patients. Seven patients (32%) had at
least one delay of treatment and five patients (23%) had
one dose reduction. The main reason for these delays and
dose reductions was complication due to adverse events.
Clinical responses
Only seven patients completed at least four cycles of
vorinostat treatment (two in arm A, five in arm B, see
below). In arm A, the confirmed CR rate was 0% (95%
CI, 0% to 23%).The arm was closed at the interim analy-
sis since none of the first 13 patients enrolled had an
unconfirmed HI, PR or CR at the cycle-4 evaluation. Arm
B passed interim analysis since one patient had an uncon-
firmed HI at the cycle-4 evaluation. Among all 22 enrolled
patients in arm B, the confirmed CR rate was 4.5% (one
response; 95% CI, 0.4% to 24%). The single responding
patient was a 77-year old woman with untreated AML
M4 who presented with a WBC count of 3.4×109/L, 36%
monocytes, and 34% blasts. Cytogenetic analysis was
unsuccessful in this patient. The woman had an improve-
ment in hematologic parameters (platelets and neu-
trophils) following cycle 2 of treatment. She was first clas-
sified as having obtained a CR at the cycle-4 evaluation,
and the CR was confirmed at the cycle-6 evaluation more
than 6 weeks later. The duration of response was at least
398 days, as the patient was still responding at the last
recorded follow-up. No partial responses (unconfirmed or
otherwise) have been noted in either arm. Overall, the
decision criteria to claim the treatment promising (at least
three confirmed CR) was not met in either arm.
Survival models
The median TTF in arm A was 42 days (95% CI, 26 to
57). Eleven patients (79%) received no more than two
Table 3. Maximum severity of adverse events for arm A patients.
Adverse event Gr.1 Gr.2 Gr.3 Gr.4 Gr.5
Thrombocytopenia 1 0 4 10 0
Neutropenia 1 2 1 10 0
Anemia 1 2 3 1 0
Leukopenia 1 1 1 3 0
Fatigue 2 4 7 1 0
Death NOS 0 0 0 0 1
Disease progression 0 0 0 0 1
Rash/desquamation 0 3 0 0 0
Nausea 2 4 1 0 0
Anorexia 2 2 0 0 0
Diarrhea 2 0 1 0 0
Vomiting 0 2 0 0 0
CNS hemorrhage 0 0 0 1 0
Febrile neutropenia 0 0 2 0 0
Pneumonia NOS 0 0 0 0 1
Dizziness 0 0 1 1 0
Dyspnea 3 1 3 0 0
Results are expressed as worst adverse event (regardless of attribution) per patient
using the National Cancer Institute Common Criteria version 3.0 toxicity-grading
criteria.
Table 4. Maximum severity of adverse events for arm B patients.
Adverse event Gr.1 Gr.2 Gr.3 Gr.4 Gr.5
Thrombocytopenia 0 1 6 13 0
Neutropenia 0 0 3 17 0
Anemia 0 3 3 1 0
Leukopenia 0 0 3 1 0
Fatigue 4 7 9 1 0
Sudden death 0 0 0 0 1
Nausea 8 5 3 0 0
Anorexia 2 4 3 0 0
Diarrhea 5 3 6 0 0
Vomiting 4 3 3 0 0
CNS hemorrhage 0 0 0 1 0
Febrile neutropenia 0 0 6 0 0
Pneumonia 0 0 3 0 0
Pneumonitis 0 0 0 0 1
Acidosis 0 0 0 1 0
Pain-abdominal 2 1 0 0 0
Pain-pleuritic 0 0 0 1 0
Hypoxia 0 0 1 1 0
Dyspnea 2 4 1 0 0
Results are expressed as worst adverse event (regardless of attribution) per patient














cycles of treatment, and two patients each (14%)
received three and four cycles of treatment. No patients
in arm A continued treatment after the cycle-4 evalua-
tion. The median TTF in arm B was 46 days (95% CI, 20
to 71). Thirteen patients (59%) received no more than
two cycles of treatment. Four patients (18%) received
three cycles of treatment, three patients (14%) received
four cycles, one patient received six cycles, and one
patient received all 17 cycles of treatment as specified by
the protocol. The reasons for discontinuation of treat-
ment were death (3 patients in arm A, 2 patients in arm
B), adverse events (1 in arm A, 2 in arm B), alternative
treatment (4 in each arm), failure to achieve a WBC count
less than 30×109/L after two cycles of treatment (2 in each
arm), patients’ refusal (1 in arm A, 4 in arm B), other med-
ical problems (1 in arm A), physicians’ decision (1 in each
arm), and disease progression (1 in arm A, 3 in arm B).
TTF and survival were similar in untreated and
relapsed patients. The median TTF was 41 days (95% CI:
24 to 53) for untreated patients and 42.5 days (95% CI:
41 to 65) for the relapsed group. The median survival was
41 days (95% CI: 27 to 290) in the untreated group and
149 days (95% CI: 81 to 221) in the relapsed group.
To examine whether the high failure rate was due pri-
marily to the inability of vorinostat to control hyper-
leukocytosis, we examined the number of cycles of ther-
apy administered to patients based on their presenting
WBC counts. Ten patients (71%) in arm A and 14
patients (64%) in arm B began treatment with baseline
WBC counts of less than 5×109/L; none of these patients
was receiving hydroxyurea. Conversely, five patients
began treatment with baseline WBC counts over
30×109/L (3 in arm A and 2 in arm B). Only two of these
patients received more than two cycles of vorinostat (1 in
each arm). Eleven patients received hydroxyurea at some
point during therapy. Five patients (36%) in arm A and
eight patients (36%) in arm B had WBC counts over
30×109/L during at least one cycle of treatment. These
patients with high WBC counts received a median of two
cycles of therapy in either arm with the following ranges:
arm A, 1 - 3; arm B, 1- 4. Among the seven patients in
either arm who received at least four cycles of therapy,
the baseline WBC count was 2.5×109/L (range, 1.3 – 5.4).
After categorizing patients into those with low baseline
WBC counts (≤5×109/L) and high baseline WBC counts
(>5×109/L), the median number of cycles of treatment
administered was two for both the groups with low and
high WBC counts in each arm. Patients in arm A with
both high and low baseline WBC counts received
between one and four cycles of treatment. In arm B, the
range for the group with a low baseline count was 1 to
17, while the range for the group with a high baseline
WBC count was 1 to 4 cycles.
Fourteen of the 15 patients (93%) in arm A have died,
and 21 of the 22 patients (95%) in arm B have died. The
median overall survival was 105 days (95% CI, 55 to 223)
in arm A and 153 days (95% CI, 58 to 229) in arm B.
Discussion
In this multicenter, open-label, randomized phase 2
trial, the primary objective was to determine the
response rate associated with two dosing schedules of
vorinostat for the treatment of patients with relapsed
AML and selected untreated patients with high-risk
AML. Only one confirmed CR was observed in the first
37 patients enrolled in the study. In addition, no partial
responses were noted in either arm. Overall, the decision
criteria to claim the treatment promising (at least three
confirmed CR) was not met in either arm. These results
are inferior to those obtained with cytotoxic chemother-
apy and other recently reported biological therapies and
do not confirm the promising activity noted for a similar
dosing schedule reported in a phase I study in AML.32 In
that study, seven of 31 AML patients experienced hema-
tologic improvement, including two CR and two CR
with incomplete blood count recovery. Four of the
patients with responses were treated with a dose sched-
ule corresponding to that used in arm B of the current
trial. That cohort accrued a total of 12 patients in the
phase I study. The median number of cycles until
response or improvement developed was two (range, 1-
8); however, the median duration of response was only 6
weeks (range, 0.1-53 weeks). While it is possible that the
different case mix in the present study from that in the
previously published phase I study accounts for the dif-
ference in results, it is more likely that these reflect the
disappointing response rate to vorinostat monotherapy
in a real-world multicenter phase 2 trial.
It is noteworthy that even in a small consortium of aca-
demic institutions, a large number of patients exited the
trial prior to receiving the planned four cycles. AML ther-
apy has traditionally been developed based on the
achievement of complete remission within one to two
cycles of therapy. Physicians and patients may become
impatient waiting several cycles for response, particular-
ly in the context of declining performance status. This
may have accounted for the low median number of
cycles (n=3) delivered to patients with myelodysplastic
syndromes in the US registration trial of decitabine
despite published data suggesting that four to six cycles
were required for a response to be demonstrated.36
Successful development of agents targeting epigenetic
therapies which do not act as rapidly as conventional
cytotoxic agents requires thoughtful attention to physi-
cians’ and patients’ expectations in order to enable suffi-
cient treatment to be administered.
Biological features of the leukemia may account for
resistance to vorinostat and other HDAC inhibitors.
HL60 cells cloned for HDAC inhibitor resistance (HL-
60/LR) cells demonstrate resistance to LAQ824, vorinos-
tat, LBH589, and sodium butyrate. These cells show loss
of HDAC6, hyperacetylation of HSP90, an aggressive
leukemia phenotype, and collateral sensitivity to 17-
AAG.37 An increased expression of the antioxidant signa-
ture in lymphoma and AML patients has been correlated
as a biomarker for vorinostat resistance, given the fact
that vorinostat-induced cytotoxicity has been shown to
be blocked by up-regulation of reactive oxygen species in
previous clinical and pre-clinical studies.38-40
The results of this study do not enable either of the
two dosing schedules to be recommended for further
study as monotherapy in AML. Both regimens of vorino-
E.W. Schaefer et al. 
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stat were generally well tolerated. Although drug-related
adverse experiences were noted in all patients, these
events were mostly mild to moderate in severity and
rarely resulted in dose reduction or discontinuation in the
arm in which 400 mg daily was administered. The group
of patients who received 200 mg t.i.d. had a significantly
higher incidence of gastrointestinal adverse events that
resulted in delays of treatment in almost a quarter of the
patients (23%). The single responding patient received
intermittent dosing, the schedule which was selected
based on responses in the previous phase I trial.32 The
remarkable duration of complete remission for this partic-
ular patient confirms the anecdotal observation from the
phase I study that isolated patients may in fact respond
meaningfully to HDAC inhibitor monotherapy. At pres-
ent, there is inadequate information about the biology of
such patients in order to enable appropriate selection of
patients. 
Development of epigenetically targeted agents may
benefit from pharmacodynamically-driven dose-finding
studies rather than classical determination of maximum
tolerated dose. However, HDAC inhibitors such as
vorinostat have a panoply of molecular effects. Without
knowing which molecular end-points drive clinical
response (for example, gene re-expression, HSP90 inacti-
vation, generation of reactive oxygen species) selecting a
dose and schedule based on a single pharmacodynamic
end-point may lead to the problem of underdosing.
The short survival of patients in this trial stands in stark
contrast to recent results with 5-azacytidine in patients
with high-risk myelodysplastic syndrome. In that study,
the 2- year survival was twice that of patients receiving a
combined conventional care regimen, despite an extreme-
ly low complete remission rate.45 Whether this reflects a
difference between DNA methyltransferase monothera-
py and HDAC inhibitor monotherapy, a difference
between high-risk myelodysplastic syndrome (including
AML with trilineage dysplasia) and, more generally, AML
in the elderly, which includes patients with more prolifera-
tive biology, or differences between a biologically active
drug (5-azacytidine) and one which is less active for this
disease (vorinostat) remains speculation.
Although vorinostat as monotherapy in these patients
did not show sufficient activity to justify further develop-
ment in AML, a variety of pre-clinical models suggest that
HDAC inhibitors may potentiate epigenetic and cytotox-
ic effects of other agents. These include HSP90
inhibitors,39 proteosome inhibitors,41 conventional cyto-
toxic chemotherapy drugs42,43 and DNA methyltransferase
inhibitors.44 As of November 2008, there were 102 trials
(63 recruiting, 59 completed, terminated or not recruiting)
on the use of vorinostat in multiple types of cancer includ-
ing hematologic malignancies, advanced solid tumors,
breast cancer, gliomas, melanoma, kidney cancer, ovarian
cancer, prostate cancer, colorectal cancer, and thyroid can-
cer (http://clinicaltrials.gov). Future pre-clinical and clinical
trials will need to focus on potential synergistic effects of
vorinostat with other agents and to establish low and
high vorinostat-resistance profiles, in order to optimize
the use of this and other HDAC inhibitors for the treat-
ment of leukemia and other cancers.
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responding patient.
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